The presence of mutations within the PIK3CA/AKT pathway indicates a potential for targeted therapeutic trials with newer generation of PIK3CA inhibitors, either alone or in combination with other therapies.44, 45 Recently, a PIK3CA inhibitor was FDA approved for the treatment of ER‐positive/HER2‐negative breast cancers harboring known pathogenic PIK3CA mutations in combination with anti‐ER therapy (fulvestrant) (FDA site, accessed October 12, 2019). This evidence concerns the gene ERBB2 and breast carcinoma.